Biosimulation
plays important role in research and development process.
Biosimulation is widely used in consumer personalized medicine, owing
to increasing demand for personalized medicine in offering tailored
solutions for various treatment areas such as drug discovery,
oncology, cardiology, infectious disease, and psychiatry. Predictive
biosimulation offers effective platform to use biological data and
mathematical modeling to create a virtual version of patient to test
simulated treatments.
Moreover,
continuous research is being conducted to create a low-priced or open
source version of predictive biosimulation platforms for
self-tracking and modeling using patient’s data and to speed up the
adoption by software development communities to generate future
health scenarios using patient’s medication data.
Get
In-Depth Sample Copy of This Research @
https://www.coherentmarketinsights.com/insight/request-sample/2016
Market
Dynamics
Market
players are engaged in developing novel biosimulation platform, in
order to offer tailored solution in each therapeutic area. This is
expected to aid in growth of the market. For instance, in October
2013, Rhenovia Pharma: a biotechnology firm specialized in
biosimulation has developed the first simulator for biological
mechanism of epilepsy. Moreover, development of new simulator opens
new possibilities for research in epilepsy treatment. Rhenovia’ new
simulator replicates the basic biological mechanisms of signal
transmission between brain cells and simulates its defects leading to
epileptic patterns, thereby leading to prevent epileptic seizures.
Growing
support from heathcare regulatory organizations in the adoption of
biosimulation based software and services will, augment future growth
of biosimulation market. Current FDA and EMA guidelines recommends
the use of biosimulation in pediatric drug development studies,
thereby minimizing the impact on children that must enroll in
clinical trials. For instance, in Novembr 2017, Certara stated that
U.S. Food and Drug Administration (FDA), expanded its use of
Certara’s PBPK Simcyp Population-based Simulator and its Pediatric
and Cardiac Safety Simulators. In addition, under the new agreement,
FDA has tripled its number of licenses, equipping its Modeling and
Simulation (M&S) review team with almost 60 PBPK licenses.
Accelerated
drug discovery development process by key players to favor market
growth
Pharmaceutical
companies, non-profit organizations, and healthcare regularity
organizations are majorly investing in research and development of
drug discovery process. Market players are engaged in exploiting
biosimulation techniques for enhancing efficacy of drug discovery and
development process, which is expected to drive growth of the
biosimulation market. Government of various economies are funding
initiatives such as Innovate UK and Horizon 2020 provide businesses
and research organizations with grants to drive scientific research.
Innovate UK is the UK’s innovation agency and part of UK Research
and Innovation, which supported two companies, Adorial Pharma Limited
and C4X Discovery, in enabling the development of a novel
mathematical-based system of drug discovery.
Global
Key Players
Key
players operating in biosimulation market include Certara, L.P.,
Simulations Plus, Inc., Dassault Systèmes (Accelrys), Genedata AG,
LeadScope, Inc., Compugen Inc., Schrödinger, LLC, In Silico
Biosciences, Inc., Advanced Chemistry Development, Inc., Chemical
Computing Group ULC, Physiomics PLC, and Pharmaceutical Product
Development, LLC (Evidera).
Detailed
Segmentation:
Global
Biosimulation Market, By Product & Services:
-
Software
-
Services
Global
Biosimulation Market, By Application:
-
Drug Discovery
-
Drug Development
Browse
Research Report @
https://www.coherentmarketinsights.com/market-insight/biosimulation-market-2016
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment